1. Antibody–drug conjugates for lung cancer in the era of personalized oncology
   Biagio Ricciuti et al, 2021, Seminars in Cancer Biology CrossRef
2. Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor
   Takahito Hara et al, 2020, Biochemistry and Biophysics Reports CrossRef
3. c-Met: A Promising Therapeutic Target in Bladder Cancer
   Yanfei Feng et al, 2022, Cancer Management and Research CrossRef
4. Role of miR-944/MMP10/AXL- axis in lymph node metastasis in tongue cancer
   Bhasker Dharavath et al, 2023, Communications Biology CrossRef
5. Colorectal cancer associated with parathyroid hormone-related protein (review)
   A. N. Kurzanov et al, 2024, Koloproktologia CrossRef
6. Involvement of Met receptor pathway in aggressive behavior of colorectal cancer cells induced by parathyroid hormone-related peptide
   María Belén Novoa Díaz et al, 2022, World Journal of Gastroenterology CrossRef
7. SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models
   Chun‐Bong Synn et al, 2022, Clinical & Translational Immunology CrossRef
8. Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma
   Yeliz Yılmaz et al, 2021, Liver Cancer in the Middle East CrossRef
9. AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew
   Almira Auyez et al, 2021, Cancers CrossRef
10. Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non‑small cell lung cancer (Review)
    Hiu Lee et al, 2021, Oncology Letters CrossRef
11. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma
    Antonino Belfiore et al, 2019, International Journal of Molecular Sciences CrossRef